Abstract
Positron emission tomography (PET)‐guided strategies emerge as standard‐of‐care for advanced‐stage classical Hodgkin lymphoma (cHL) while conflict remains regarding early stage (I – IIa) disease and the necessity for treatment‐intensification among patients with a positive PET after two chemotherapy cycles (PET‐2) (Borchmann et al, 2017). Risk‐stratification remains crucial, increasing the requirement for predictive biomarkers.
...
...
| Original language | English |
|---|---|
| Journal | British Journal of Haematology |
| Volume | 184 |
| Issue number | 5 |
| Pages (from-to) | 869-873 |
| Number of pages | 5 |
| ISSN | 0007-1048 |
| DOIs | |
| Publication status | Published - 01.03.2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)
Fingerprint
Dive into the research topics of 'The Glasgow prognostic score at diagnosis is an independent predictor of survival in advanced stage classical Hodgkin lymphoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver